Compare Cadila Healthcare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AJANTA PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AJANTA PHARMA CADILA HEALTHCARE/
AJANTA PHARMA
 
P/E (TTM) x 24.6 24.6 99.9% View Chart
P/BV x 4.3 6.8 63.1% View Chart
Dividend Yield % 0.8 0.5 155.3%  

Financials

 CADILA HEALTHCARE   AJANTA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
AJANTA PHARMA
Mar-19
CADILA HEALTHCARE/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3521,422 24.8%   
Low Rs207898 23.0%   
Sales per share (Unadj.) Rs139.2233.5 59.6%  
Earnings per share (Unadj.) Rs11.844.0 26.8%  
Cash flow per share (Unadj.) Rs18.652.2 35.6%  
Dividends per share (Unadj.) Rs3.509.00 38.9%  
Dividend yield (eoy) %1.30.8 161.4%  
Book value per share (Unadj.) Rs101.4255.1 39.7%  
Shares outstanding (eoy) m1,023.7488.02 1,163.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.05.0 40.4%   
Avg P/E ratio x23.726.4 90.0%  
P/CF ratio (eoy) x15.022.2 67.7%  
Price / Book Value ratio x2.84.5 60.6%  
Dividend payout %29.820.5 145.3%   
Avg Mkt Cap Rs m286,033102,081 280.2%   
No. of employees `00013.46.8 197.1%   
Total wages/salary Rs m24,1454,307 560.6%   
Avg. sales/employee Rs Th10,632.73,022.6 351.8%   
Avg. wages/employee Rs Th1,801.2633.4 284.4%   
Avg. net profit/employee Rs Th898.5569.1 157.9%   
INCOME DATA
Net Sales Rs m142,53120,554 693.5%  
Other income Rs m1,139211 540.3%   
Total revenues Rs m143,67020,765 691.9%   
Gross profit Rs m24,1985,664 427.2%  
Depreciation Rs m6,965721 966.3%   
Interest Rs m3,41812 29,465.5%   
Profit before tax Rs m14,9545,143 290.8%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1981,273 251.2%   
Profit after tax Rs m12,0443,870 311.2%  
Gross profit margin %17.027.6 61.6%  
Effective tax rate %21.424.8 86.4%   
Net profit margin %8.518.8 44.9%  
BALANCE SHEET DATA
Current assets Rs m87,15411,812 737.8%   
Current liabilities Rs m82,6943,776 2,189.8%   
Net working cap to sales %3.139.1 8.0%  
Current ratio x1.13.1 33.7%  
Inventory Days Days7177 92.3%  
Debtors Days Days9482 115.0%  
Net fixed assets Rs m133,23614,398 925.4%   
Share capital Rs m1,024175 583.8%   
"Free" reserves Rs m102,73322,277 461.2%   
Net worth Rs m103,75722,452 462.1%   
Long term debt Rs m32,1467 487,060.6%   
Total assets Rs m236,86626,962 878.5%  
Interest coverage x5.4444.3 1.2%   
Debt to equity ratio x0.30 105,395.6%  
Sales to assets ratio x0.60.8 78.9%   
Return on assets %6.514.4 45.3%  
Return on equity %11.617.2 67.3%  
Return on capital %13.723.0 59.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75210,682 493.9%   
Fx outflow Rs m14,5042,102 690.0%   
Net fx Rs m38,2488,580 445.8%   
CASH FLOW
From Operations Rs m25,0543,748 668.5%  
From Investments Rs m-10,123-2,228 454.4%  
From Financial Activity Rs m-10,942-1,475 742.0%  
Net Cashflow Rs m3,98945 8,825.2%  

Share Holding

Indian Promoters % 74.8 73.8 101.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 1.6 535.5%  
FIIs % 5.9 7.6 77.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.0 64.7%  
Shareholders   44,069 20,968 210.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WOCKHARDT  J.B.CHEMICALS  SHASUN PHARMA  STRIDES PHARMA SCIENCE  FULFORD INDIA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 25, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ORCHID PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS